Components of clinical trials for vasovagal syncope

Europace

Volumn 3, Issue 3, 2001, Pages 233-240

  Rose, S ^a   Sheldon, Robert ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cost utility; Drug therapy; Pacemaker therapy; Quality of life; Randomized clinical trials; Tilt table test; Vasovagal syncope

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ETILEFRINE; METOPROLOL; MIDODRINE; PAROXETINE; PLACEBO;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HEART PACING; HISTORY; HUMAN; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYMPTOM; SYNCOPE; TILT TABLE TEST; TIME;

CLINICAL TRIALS; DOUBLE-BLIND METHOD; FORECASTING; HUMANS; MULTICENTER STUDIES; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SYNCOPE, VASOVAGAL; TIME FACTORS;

EID: 0034933722     PISSN: 10995129     EISSN: None     Source Type: Journal    
DOI: 10.1053/eupc.2001.0168     Document Type: Article

References (42)

1. Rules of evidence and clinical recommendations on the use of antithrombotic agents
2. Tilt table testing for assessing syncope
3. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomized, double-blind, placebo-controlled study
4. Usefulness of transdermal scopolamine for vasovagal syncope
5. Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope
6. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study
7. Tilt training: A new treatment for recurrent neurocardiogenic syncope and severe orthostatic intolerance
8. Effect of etilefrine in preventing syncopal recurrent in patients with vasovagal syncope. A double blind, randomized, placebo-controlled trial
9. Midodrine: A role in the management of neurocardiogenic syncope
10. Randomized placebo controlled assessment of midodrine in the treatment of neurocardiogenic syncope
11. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table tests results
12. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope
13. Effect of beta blockers on the clinical outcome of patients after a positive isoproterenol-tilt table test
14. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: A prospective, double-blind, randomized and placebo-controlled study
15. A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope
16. Dual chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope. Pacemaker versus no therapy: A multicentre randomized study
17. Isoproterenol induction of vasodepressor-type reaction in vasodepressor-prone persons
18. Response to head-up tile testing in patients with situational syncope
19. Provocation of hypotension during head-up tilt testing in subjects with no history of syncope or presyncope
20. Head-up tile test. A nonspecific method of evaluating patients with bifascicular block
21. Utility of a single-stage isoproterenol tilt table test in adults. A randomized comparison with passive head-up tilt
22. Tilt tolerance of young men and young women
23. Comparison of patients with syncope or unknown cause having negative or positive tilt table tests
24. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope
25. Syncope recurrence can be better predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope
26. Recurrence of neurocardiogenic syncope without pharmacologic interventions
27. Risk factors for syncope recurrence after a positive tilt table test in patients with syncope
28. Timing of first syncope recurrence predicts syncope frequency following a positive tile table test
29. The clinical and prognostic significance of the asystolic response during the head-up tilt test
30. Relevance of asystole during head-up tilt testing
31. Antecedent psychological factors in the onset of vasovagal syncope
32. Impairment of physical and psychosocial function in recurrent syncope
33. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope
34. The relationship between health related quality of life and frequency of spells in patients with syncope
35. Recurrent syncope as a chronic disease: Preliminary validation of a disease-specific measure of functional impairment
36. Cost-utility analysis of pacemakers for the treatment of vasovagal syncope
37. Effect of dual-chamber pacing with automatic rate-drop sensing on recurrent neurally mediated syncope
38. Designing clinical trials for paroxysmal atrial tachycardia and other paroxysmal arrhythmias
39. Cost and health implications of cholesterol lowering
40. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tile
41. A controlled trial of acute and long-term medical therapy in tilt-induced neurally mediated syncope
42. Limitations of head-up tile test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: Results of a controlled study of etilefrine versus placebo